

Food and
Companionship
Enriching Life

Elanco

TM



Notices and Disclaimers

Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2026 full year guidance, long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance and financial condition, and including, in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including but not limited to the following: operating in a highly competitive industry; the success of our research and development (R&D), regulatory approval and licensing efforts; the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein; competition from generic products that may be viewed as more cost-effective; changes in regulatory restrictions on the use of antibiotics in farm animals; an outbreak of infectious disease carried by farm animals; risks related to the evaluation of animals; consolidation of our customers and distributors; an increased use of alternative distribution channels or changes within existing distribution channels; our dependence on the success of our top products; our ability to complete acquisitions and divestitures and to successfully integrate the businesses we acquire; our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements; manufacturing problems and capacity imbalances, including at our contract manufacturers; fluctuations in inventory levels in our distribution channels; risks related to the use of artificial intelligence in our business; our dependence on sophisticated information technology systems and infrastructure, including the use of third-party, cloud-based technologies, and the impact of outages or breaches of the information technology systems and infrastructure we rely on; the impact of weather conditions, including those related to climate change, and the availability of natural resources; demand, supply and operational challenges associated with the effects of a human disease outbreak, epidemic, pandemic or other widespread public health concern; the loss of key personnel or highly skilled employees; adverse effects of labor disputes, strikes and/or work stoppages; the effect of our substantial indebtedness on our business, including restrictions in our debt agreements that limit our operating flexibility and changes in our credit ratings that lead to higher borrowing expenses and restrict access to credit; changes in interest rates that adversely affect our earnings and cash flows; risks related to the write-down of goodwill or identifiable intangible assets; the lack of availability or significant increases in the cost of raw materials; risks related to foreign and domestic economic, political, legal and business environments; risks related to foreign currency exchange rate fluctuations; risks related to underfunded pension plan liabilities; our current plan not to pay dividends and restrictions on our ability to pay dividends; the potential impact that actions by activist shareholders could have on the pursuit of our business strategies; risks related to tax expense or exposures; actions by regulatory bodies, including as a result of their interpretation of studies on product safety; the possible slowing or cessation of acceptance and/or adoption of our farm animal sustainability initiatives; the impact of increased regulation or decreased governmental financial support related to the raising, processing or consumption of farm animals; risks related to tariffs, trade protection measures or other modifications of foreign trade policy; the impact of litigation, regulatory investigations and other legal matters, including the risk to our reputation and the risk that our insurance policies may be insufficient to protect us from the impact of such matters; challenges to our intellectual property rights or our alleged violation of rights of others; misuse, off-label or counterfeiting use of our products; unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products; insufficient insurance coverage against hazards and claims; compliance with privacy laws and security of information; risks related to environmental, health and safety laws and regulations; and inability to achieve goals or meet expectations of stakeholders with respect to environmental, social and governance matters. For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company's latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. We undertake no duty to update forward-looking statements.

Non-GAAP Financial Measures. This presentation contains non-GAAP financial measures, such as organic constant currency (CC) revenue growth, adjusted gross profit, adjusted gross margin, adjusted net income, adjusted earnings per share (EPS), EBITDA, adjusted EBITDA and adjusted EBITDA margin and net debt and net debt leverage, which we use to assess and analyze our operational results and trends. Reconciliation of non-GAAP financial measures and reported GAAP financial measures are included in the tables in the appendix to this presentation and are posted on our website at www.elanco.com. These non-GAAP measures are not, and should not be viewed as, substitutes for U.S. GAAP reported measures.

Touching nearly every person, every day

Elanco

**WE
ENRICH
LIVES**



Elanco: A Diverse, Durable Animal Health Company with 70+ Years of Heritage...



\$4.7B


annual revenue
(2025)



90+

Countries Served

U.S.



International



10 Blockbusters

>\$100M annual revenue



#1 in Pet Health Retail


#1 in Pet Health Vet Growth

#2 in Global Farm Animal

Pet Health



Farm Animal




Elanco

4

Note: Rankings represent market share based on Elanco estimate of global animal health market. Revenue percentages are based on 2025 and exclude revenue contribution from contract manufacturing. #2 Global Farm Animal position is based on Cattle, Swine, Poultry

Executing a Clear Path to Sustainable Value Creation



Deeply Experienced Animal Health Executive Team

Driving Growth, Innovation and Cash



Jeff Simmons
CEO

Consistent Flow of Innovation



Ellen de Brabander
Research & Development

Fueling Pipeline & Portfolio



Tim Bettington
Center for Strategic Growth

Elanco Ascend Margin & Cash



Bob VanHimbergen
Chief Financial Officer

Risk & Access



Shiv O'Neill
General Counsel

Customer & Portfolio Value Driving Growth



Jose Simas
U.S. Farm Animal



Ramiro Cabral
International



Bobby Modi
U.S. Pet Health

Reliable Supply & Productivity



Grace McArdle
Manufacturing & Quality

Culture & Engagement



Dave Kinard
Human Resources

The Attractiveness of Investing in Animal Health

Durable & Diverse Industry with a Path from \$42 Billion to \$60 Billion

1 Regulated, Science-Based Industry “Pharma-Like”

- High complexity, high barrier to entry
- Innovation revolution with innovation being rewarded
- Independence = access and ownership of innovation

2

Brand Driven “CPG-Like”

- Vet and pet owner: Brand loyalty
- Protein companies: Quality assurance and brand protection
- Limited patent cliffs
- Continuous lifecycle management

3

Value Orientation “Economic Driven”


- Cash pay market: Holistic value proposition essential
- Size & scale matter
- Highly complex: Species therapeutic classes, geographies
- Requires customer interface



A Global Shift in Pet Owner Behavior

Access, Convenience and Willingness to Spend

Convenience Is King



#1

driver of treatment
adherence:
convenience¹

*Pet owners are
taking on more of
the decision-making power*

Increase Spend Across Channels



+30%

higher annual spend from
omnichannel vs.
single channel²

*Global industry momentum
centers on omnichannel access
and innovation*

Subscriptions Drive Passive Spending



40%

pet care
dollars from
subscription sales³

*A third of pet owners state
spending more on their pets than
on their own health needs⁴*

Humanization of Pets Globalizing



70%

global pet ownership
growth from emerging
markets⁵

*China and Brazil among
fastest growing pet care
markets*

¹AAHA Dec 2023 Trends Magazine ³NielsenIQ data

²McKinsey Omnichannel research

⁴U.S. News 2026 Pet Owner Survey

⁵Euromonitor, The World Market for Pet Care

Accelerating Global Animal Protein Consumption

Projected to Grow at 5% Annually in the U.S. Alone³

Overwhelming Consumer Demand




61%

U.S. consumers seeking protein increase¹

High-protein diets are now the most popular eating pattern in the U.S.

Dietary Guidelines Recommendations



~2x

recommended daily protein consumption

FDA Dietary Guidelines recommend 1.2-1.6g/kg of protein per day

GLP-1 Usage



~40-50%

more protein consumption for GLP-1 users²

21% of Americans projected to be on a GLP-1 by 2035³

Muscle Retention in Aging Population



25%

increase in adults over 60 by 2030⁴

Higher protein intake is essential in healthy aging

¹Cargill 2025 Protein Profile
²Helmsman Group, The GLP-1 Revolution

³Morgan Stanley Protein research
⁴World Health Organization

Global Pet Health
Strategic Framework



Vision
Helping pets
live longer,
healthier, more
active lives



Parasiticides

Omnichannel offerings with retail leadership and innovation to drive growth in largest pet health market



Dermatology

Differentiated entrant into fast growing global market with robust pipeline including monoclonal antibody product and multiple shots on goal




Pain & Other Therapeutics

Broad portfolio for dogs and cats, including pain products across modes of action, indications, and disease stages



Vaccines¹

Prevention coverage for a number of important pet health risks



Market Positioning

One of only two animal health companies to have full pet health portfolio



**Pet Health
Key Enablers**

Innovation Address unmet needs and expand portfolio

Share of Voice Increase product awareness with our customers

Physical Availability Maximize access to our products

Price Execution Optimize value based on willingness to pay

Global Farm Animal Strategic Framework




Vision

Helping farmers improve animal health and wellbeing, and raise livestock more sustainably



Farm Animal Key Enablers

Market Positioning



Efficiency & Performance

Market leading portfolio of medicated feed additives that increase production efficiency providing value for the producer



Disease Prevention & Treatment

Trusted partners with best-in-class products and services that create solutions to animal health challenges



Food Safety

Partnering with producers by offering a portfolio of vaccines, insecticides, and feed additives and serving as a leading industry advocate



Sustainability

Building new market with portfolio of innovative sustainability solutions that provide an economic benefit to cattle farmers



Portfolio Comprehensive, complementary product offerings


Value Beyond Product Data and analytics to drive improved outcomes

Innovation Solutions to producers' greatest challenges

Price Execution Optimize value based on willingness to pay

Elanco's **IPP Strategy** to Deliver Value to All Stakeholders

Deliver a
consistent flow of
high-impact
Innovation




Consistently
strengthen our
diverse **Portfolio** to
grow market share

Consistently improve
Productivity and cash
flow

The Results Our Strategy Are Delivering

1

Growth



2

Innovation



3


Cash




1. GROWTH

Our Transformation to a Sustainable **Growth** Company Continues

Organic Constant Currency Revenue Growth



Innovation: Big 6 Now Expected to Drive \$1.25B in Incremental Revenue in 2026



Note: Innovation revenue is incremental in reference to 2020 sales and does not include the expected impact of cannibalization on the base portfolio

Next Wave Innovation Portfolio to Deliver 5-6 Potential Blockbuster Approvals Through 2031

>15 Projects[†] in 8 Innovation Spaces

Projects

	Parasiticides	3
	Infectious Disease	Multiple
	Dermatology	3
	Pain	3
	Sustainability	2
	Obesity	2
	Chronic Kidney Disease	1
	Dermatology	1

Powerful Next Wave Profile

- ✓ All are **first/best** in class or **differentiated**
- ✓ **>\$2B** peak sales potential¹
- ✓ **5-6** potential blockbuster approvals expected in 2026-2031
- ✓ Mostly from **in-house** discovery and capabilities

[†]Total number of R&D projects is >150 distributed between, research, development and brandmax. *Multiple vaccine projects combined to equal blockbuster potential. ¹Non-risk-adjusted, excl. cannibalization
Note: Not all pipeline projects listed may make it through to approval or meet the indicated timing window due to the inherent uncertainty of scientific outcomes and differences in regulatory pathways and timelines around the world. Peak sales potential of approved products may vary significantly depending on both the regulatory claimset achieved and competitive landscape during the product lifecycle

Strengthened Balance Sheet with Improving **Cash** Generation

Capital Allocation Priorities



Debt Paydown

Primary use of free cash flow

Targeting below 3x over time



Investment
in Business

R&D, manufacturing capex,
bolt-on M&A, commercial
launches investment expected to
drive sustainable topline growth

Substantial Improvement to Adj. Net
Leverage Ratio

5.6x

4.3x

3.6x

2023

2024

2025

Anticipate Future Capital Allocation Flexibility as Net Leverage Ratio Expected to Move Below 3x

Appendix



Elanco

TM

Revenue Performance by Top Ten Countries

	Total	% of Total	Organic CC Change ¹
 United States	\$2,234	47%	10%
 Brazil	\$199	4%	8%
 United Kingdom	\$173	4%	5%
 China	\$172	4%	(4)%
 Italy	\$131	3%	6%
 France	\$128	3%	6%
 Canada	\$125	3%	8%
 Mexico	\$115	2%	2%
 Spain	\$103	2%	13%
 Japan	\$97	2%	12%
Other International	\$1,238	26%	6%
Total	\$4,715	100%	7%

Reported revenue in millions. Numbers may not add due to rounding.

¹Organic CC growth represents revenue growth excluding the impacts from our prior year divestiture of the aqua business, which was divested July 9, 2024, royalty revenue that was sold to a third party and the impact of foreign exchange rates.

Revenue Performance for Select Products

	2025 Revenue	% of Total	CC Change ¹
Advantage[®] Advantix[®] Advocate[®] AdTab[™]² Chewable Tablets	\$465	10%	1%
Seresto[®]	\$378	8%	3%
Credelio[®] Quattro[™] Credelio[®] (lotilaner)³ Credelio[™] PLUS (lotilaner+milbemycin oxime)	\$358	8%	59%
Elanco Rumensin[®]	\$289	6%	Slightly Positive
Elanco Maxiban[®] Elanco Monteban[®]	\$289	6%	9%

Reported revenue in millions. Numbers may not add due to rounding.
¹Constant Currency (CC) is a non-GAAP financial measure, representing revenue growth excluding the impact of foreign exchange rates.
²Includes the entire Advantage Family line of products
³Includes Credelio Dog and Credelio Cat.

Full Year 2025

Adjusted¹ Income Statement Highlights

Including Impact from Aqua Divestiture

\$ millions, except per share values	2025	2024	Change (\$) ²	Change (%) ²
Revenue	\$4,715	\$4,439	\$276	6%
Adjusted Gross Profit	\$2,576	\$2,436	\$140	6%
Adjusted Gross Margin ³	54.9%	54.9%	NM	0 bps
Operating Expense	\$1,798	\$1,658	\$140	8%
Interest Expense, Net	\$159	\$223	\$(64)	(29)%
Other Expense	\$14	\$3	\$11	367%
Effective Tax Rate	21.8%	18.1%	NM	NM
Adjusted Net Income	\$473	\$452	\$21	5%
Adjusted Diluted Earnings Per Share	\$0.94	\$0.91	\$0.03	3%
Adjusted EBITDA	\$901	\$910	\$(9)	(1)%
Adjusted EBITDA Margin ⁴	19.2%	20.5%	NM	(130) bps

Note: Numbers may not add due to rounding.

¹Non-GAAP financial measures. See Appendix to this presentation for more information, including GAAP to non-GAAP reconciliations.

²Comparisons have not been adjusted for the unfavorable impact of the aqua divestiture which was completed on July 9, 2024.

³We define adjusted gross margin as adjusted gross profit divided by total revenue, excluding royalty revenue sold to a third party.

⁴We define adjusted EBITDA margin as adjusted EBITDA divided by total revenue, excluding royalty revenue sold to a third party.

Financial Guidance

\$ millions, except per share values

	May	August	Comments
Revenue ¹	\$5,010 - \$5,085	\$5,090 - \$5,140	6%-7% organic CC ² growth
Adjusted EBITDA ³	\$975 - \$1,005	\$1,010 - \$1,035	13% growth at midpoint
Adjusted Diluted EPS ³	\$1.03 - \$1.09	\$1.10 - \$1.16	20% growth at midpoint



Accelerating Price Contribution YoY

Reflecting our latest innovation and the value of our portfolio to customers



Adj. EBITDA Margin Expansion

Led by Elanco Ascend program, with G&A savings more front-loaded over the 5-year period



Contributions from M&A

AHV International acquisition expected to contribute 1% to reported growth for the full year

¹Revenue guidance excludes royalty revenue that was sold to a third party.

²Organic CC growth represents revenue growth excluding the impacts from royalty revenue that was sold to a third party, foreign exchange rates, and acquisitions and divestitures.

³Non-GAAP financial measure